Five Prime Therapeutics Announces Closing of Upsized Public Offering

Five Prime Therapeutics (Nasdaq:FPRX) announced today the closing of its upsized public offering of 5,897,435 shares of its common stock, which includes 769,230 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of $115 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Five Prime, and estimated net proceeds of approximately $107.6 million after deducting these amounts.
As quoted in the press release:

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC are acting as book-running managers for the offering. Wells Fargo Securities, LLC is also acting as a book-running manager for the offering.
Five Prime filed a shelf registration statement relating to the offering with the Securities and Exchange Commission (SEC), which was effective upon filing on November 3, 2016.

Click here to read the full press release.